Longstanding ataxic demyelinating polyneuronopathy with a novel autoantibody

Neurology. 2003 Jan 14;60(1):127-9. doi: 10.1212/01.wnl.0000040660.76868.3c.

Abstract

The authors describe the clinical course, postmortem findings, and characterization of a novel autoantibody (anti-M-phase phosphoprotein-1 [anti-MPP-1]) in a patient with a longstanding acquired demyelinating polyneuropathy and neuronopathy. Postmortem examination identified active sensory neuron degeneration, sensory axon loss, and widespread peripheral nerve demyelination. A possible pathophysiologic role of anti-MPP-1 is not yet identified.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma* / complications
  • Adenocarcinoma* / surgery
  • Aged
  • Ataxia / etiology*
  • Autoantibodies / blood*
  • Brain / pathology
  • Cell Cycle Proteins*
  • Disease Progression
  • Electrodiagnosis
  • Fatal Outcome
  • Ganglia, Spinal / pathology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Kinesins
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / surgery
  • Male
  • Neural Conduction
  • Phosphoproteins / immunology
  • Polyradiculoneuropathy / complications
  • Polyradiculoneuropathy / diagnosis*
  • Polyradiculoneuropathy / pathology
  • Polyradiculoneuropathy / physiopathology*
  • Precipitin Tests
  • Reaction Time
  • Spinal Cord / pathology
  • Sural Nerve / pathology

Substances

  • Autoantibodies
  • Cell Cycle Proteins
  • Immunoglobulins, Intravenous
  • Phosphoproteins
  • KIF20B protein, human
  • Kinesins